

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.2D4APPLICATION NO.
10/607,035SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Clarence N. Ahlem, et alFILING DATE
June 25, 2003GROUP
1617

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|-----------------|----------|-----------------|-------|----------|------------------------------------|
| | | | | | | |
| | 6,670,349 | 12-30-03 | Nyce | | | 01-20-00 |
| | 6,372,732 | 04-16-02 | Lardy et al. | | | 05-27-99 |
| | 6,207,703 | 03-27-01 | Ponikau | | | 10-22-98 |
| | 6,172,088 | 01-09-01 | Simpkins et al. | | | 11-24-98 |
| | 6,046,185 | 04-02-00 | Burgoyne et al. | | | 07-10-97 |
| | 6,087,351 | 07-11-00 | Nyce | | | 05-22-97 |
| | 5,837,713 | 11-17-98 | Gleich | | | |
| | 5,660,835 | 08-26-97 | Nyce | | | |
| | 5,641,768 | 06-24-97 | Loria | | | |
| | 5,506,221 | 04-09-96 | Anderson et al. | | | |
| | 5,405,842 | 04-11-95 | Silverman | | | |
| | 5,116,829 | 05-26-92 | Hori et al. | | | |
| | 4,897,390 | 01-30-90 | Ruhe | | | |
| | 4,628,052 | 12-09-86 | Peat | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, ETC.) |
|---------------------|---|
| | Auci D, et al., Anti-inflammatory and immune regulatory properties of 5-androsten-3 β ,17 β -diol (HE2100) and synthetic analogue HE3204 Implications for treatment of autoimmune diseases, <i>Ann. N.Y. Acad. Sci.</i> , 1051:730 – 742 2005 |
| | Offner H, A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse, <i>Clin. Immun.</i> , 110:181 – 190 2004 |
| | |
| | |

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.